CVS
HealthcareCVS Health
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2007–2025(19yr)| Metric | FY 2007 | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.3B | $87.5B | $98.7B | $96.4B | $107.1B | $123.1B | $126.8B | $139.4B | $153.3B | $177.5B | $184.8B | $194.6B | $256.8B | $268.7B | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B | +7.8% |
| Gross Profit | $16.1B | $18.3B | $20.4B | $20.3B | $20.6B | $22.5B | $23.8B | $25.4B | $26.5B | $28.9B | $28.5B | $38.1B | $98.1B | $104.7B | $116.3B | $125.6B | $140.7B | $166.5B | $180.9B | +8.6% |
| Gross Margin | 21.1% | 20.9% | 20.6% | 21.0% | 19.2% | 18.3% | 18.8% | 18.2% | 17.3% | 16.3% | 15.4% | 19.6% | 38.2% | 39.0% | 39.8% | 38.9% | 39.3% | 44.7% | 45.0% | +0.3pp |
| Operating Income | $4.8B | $6.0B | $6.4B | $6.2B | $6.3B | $7.2B | $8.0B | $8.8B | $9.5B | $10.3B | $9.5B | $4.0B | $12.0B | $13.9B | $13.2B | $7.7B | $13.7B | $8.5B | $4.7B | -45.3% |
| Operating Margin | 6.3% | 6.9% | 6.5% | 6.4% | 5.9% | 5.9% | 6.3% | 6.3% | 6.2% | 5.8% | 5.2% | 2.1% | 4.7% | 5.2% | 4.5% | 2.4% | 3.8% | 2.3% | 1.2% | -1.1pp |
| Net Income | $2.6B | $3.2B | $3.7B | $3.4B | $3.5B | $3.9B | $4.6B | $4.6B | $5.2B | $5.3B | $6.6B | -$594.0M | $6.6B | $7.2B | $7.9B | $4.1B | $8.3B | $4.6B | $1.8B | -61.7% |
| Net Margin | 3.5% | 3.7% | 3.7% | 3.6% | 3.2% | 3.1% | 3.6% | 3.3% | 3.4% | 3.0% | 3.6% | -0.3% | 2.6% | 2.7% | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% | -0.8pp |
| Free Cash Flow | $1.4B | $1.8B | $1.5B | $2.8B | $4.0B | $4.6B | $3.8B | $6.0B | $6.0B | $7.8B | $6.1B | $6.8B | $10.4B | $13.4B | $15.7B | $13.4B | $10.4B | $6.3B | $7.8B | +23.4% |
| FCF Margin | 1.9% | 2.0% | 1.5% | 2.9% | 3.7% | 3.8% | 3.0% | 4.3% | 3.9% | 4.4% | 3.3% | 3.5% | 4.0% | 5.0% | 5.4% | 4.2% | 2.9% | 1.7% | 1.9% | +0.2pp |
| EPS (Diluted) | $1.92 | $2.18 | $2.55 | $2.49 | $2.57 | $3.03 | $3.74 | $3.96 | $4.63 | $4.90 | $6.44 | $-0.57 | $5.08 | $5.46 | $5.95 | $3.14 | $6.47 | $3.66 | $1.39 | -62.0% |
1. THE BIG PICTURE
CVS Health is no longer just a drugstore; it is a vertically integrated healthcare giant betting that owning the insurer (Aetna), the pharmacy (CVS), and the clinic (Oak Street/Signify) will lower costs and lock in customers. However, recent results showing a $5.7 billion impairment in its delivery unit and a net margin that trails all major peers suggest the "integrated model" is currently struggling to produce the efficiencies management promised.
2. WHERE THE RISKS HIT HARDEST
- The "integrated model" advantage is threatened by inaccurate benefit cost forecasting because fixed premiums in the Health Care Benefits segment cannot be adjusted for cost overruns. This directly erodes the gains from enterprise-wide coordination if medical utilization or drug prices spike (10-K Item 1, Risks).
- Physical accessibility is threatened by adverse economic conditions because inflation and high interest rates simultaneously increase medical utilization costs while suppressing consumer demand at the 9,000 retail locations that anchor CVS Health’s "trusted relationship" strategy (10-K Item 1, Risks).
- The goal of being the "partner of choice" is threatened by price compression in the PBM and pharmacy businesses, where intense competition for government contracts forces margin-thinning bids that CVS Health may not be able to offset through scale (10-K Item 1, Risks).
3. WHAT THE NUMBERS SAY TOGETHER
CVS Health generates massive scale, with $391.8 billion in TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter revenue, but it struggles to convert that scale into profit. It currently ranks last among its peer group in both operating margin (0.9%) and net margin (-0.3%) (XBRL, Peer Benchmarking). While total revenue grew 8.2% in the most recent quarter, adjusted EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric fell to $1.09, reflecting the impact of the Inflation Reduction Act on Medicare Part D and a $5.7 billion goodwill impairment in the Health Care Delivery unit (8-K).
The divergence between GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric growth (up to $2.30) and the Adjusted EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric decline highlights the heavy noise from $1.2 billion in legacy litigation charges and the massive impairment (8-K). Furthermore, while CVS Health maintains a 3.4% dividend yield—the highest in its peer group—it has a 0.0% buyback yield, suggesting that capital is being prioritized for debt servicing on its $52.7 billion net debt rather than being returned to shareholders (Peer Benchmarking).
4. IS IT WORTH IT AT THIS PRICE?
At 9.4x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, CVS Health trades at a 34% discount to the peer median of 14.2x, making it appear attractively valued relative to competitors like UnitedHealth (14.2x) and Elevance (9.6x) (Peer Benchmarking). At this multiple, the market is pricing in a long-term growth rate of approximately 0.5% (CAPM analysis).
This low expectation is supported by CVS Health's actual fundamentals: CVS Health ranks 6th of 6 in revenue growth (+7.8%) and has a net margin of -0.3% (Peer Benchmarking). The discount is further justified by 13.4x net leverage, which is significantly higher than peers with more robust margins (CAPM analysis). If growth were to accelerate to a GDP-pace of 2.5%, the justified multiple would rise to 22.0x, but investors are currently demanding a steep discount to account for regulatory uncertainty and the risk of continued medical cost overruns (CAPM analysis, Risks).
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if the Health Care Delivery unit shows stabilization, evidenced by a lack of further goodwill impairment charges beyond the $5.7 billion already recorded (8-K).
- Constructive if net leverage (currently 13.4x) trends downward through the application of the projected $9.0 billion in 2026 operating cash flow toward aggressive debt reduction (8-K, CAPM analysis).
- Cautious if medical benefit ratios continue to exceed forecasts, proving that CVS Health cannot accurately price its fixed-premium products in an inflationary environment (Risks).
6. BOTTOM LINE
Structural Advantage: A vertically integrated "care delivery" loop that connects 9,000 retail locations and 1,000 clinics to a massive insurance and PBM member base.
Bottom Line: CVS Health is a high-leverage turnaround play that is priced for stagnation, offering significant upside only if management can translate its massive scale into the peer-level margins that have so far remained elusive.
1. Top 5 Material Risks
- Inaccurate Benefit Cost Forecasting: CVS Health prices its Insured Health Care Benefits products up to twelve months in advance. If actual medical costs exceed projections—driven by factors like pandemics, drug price inflation, or changes in member utilization—CVS Health cannot recover these costs during the fixed premium period, directly reducing segment operating results.
- Adverse Economic Conditions: Inflation, high interest rates, and unemployment threaten to increase medical utilization and fraudulent claims in the Health Care Benefits segment, while simultaneously reducing consumer demand for products in the Pharmacy & Consumer Wellness segment and lowering PBM service demand.
- Competitive Environment and Price Compression: Each segment operates in a highly competitive market where CVS Health must bid for government contracts and negotiate with PBM clients. Increased competition and client demands for lower prices lead to margin compression and potential loss of membership.
- Regulatory and Legislative Uncertainty: Changes to the ACA, Medicare, Medicaid, and PBM-related laws (such as potential prohibitions on pharmacy licensure for PBM-affiliated pharmacies) could fundamentally alter CVS Health’s business model and profitability.
- Cybersecurity and Data Governance: As a collector of vast amounts of protected health and financial information, CVS Health faces significant risks from cyberattacks and data governance failures. A breach could result in material fines, litigation, remediation costs, and reputational damage.
2. Company-Specific Risks
- Vertical Integration Scrutiny: CVS Health’s strategy of integrating PBM, pharmacy, and health care delivery services has drawn increased regulatory and public scrutiny, including state-level legislative efforts to prohibit pharmacy licensure for PBM-affiliated entities.
- Health Care Delivery Risks: CVS Health’s primary care and health risk assessment businesses (e.g., Oak Street Health and Signify Health) are uniquely dependent on Medicare reimbursement rates and specific government-funded programs, making them vulnerable to changes in CMS payment methodologies.
- Star Rating Sensitivity: Medicare Advantage operating results are heavily dependent on CMS "star ratings." With over 81% of Medicare Advantage members in 2026 plans rated 4 stars or higher, any decline in these ratings would result in the loss of quality bonuses and could lead to contract termination.
- Proprietary Brand Exposure: CVS Health’s reliance on proprietary brands in its retail stores subjects it to unique product liability, recall, and supply chain disruption risks that do not apply to third-party products.
3. Regulatory/Legal Risks
- False Claims Act and Qui Tam Litigation: CVS Health is a defendant in multiple whistleblower (qui tam) suits. An adverse decision could lead to significant fines, treble damages, and potential suspension from government programs like Medicare and Medicaid.
- Minimum MLR Rebate Requirements: The ACA and other regulations limit the margins CVS Health can earn in its Insured Health Care Benefits products. If a contract pays minimum MLR rebates for three consecutive years, it becomes ineligible for new enrollment; five consecutive years results in contract termination.
- Government Audits: CVS Health is subject to regular audits by CMS and the OIG regarding risk adjustment data and PBM network reconciliations. These audits can result in material premium refunds, fines, and penalties.
- Opioid and Talc Litigation: CVS Health is a defendant in hundreds of litigation proceedings related to the sale of opioids and products containing talc, which pose significant financial and reputational risks.
4. Financial Impact Map
Inaccurate Benefit Cost Forecasting → Health Care Benefits Operating Results → Premium deficiency reserves of $448 million (Q1 2025) and $471 million (Q2 2025) recorded for specific product lines.
Adverse Economic Conditions → Operating Results and Cash Flows → Potential for net realized capital losses in the investment portfolio and increased interest expense due to inflation-driven rate hikes.
Competitive Price Compression → Operating Income → Margin compression in PBM and retail pharmacy due to client demands for lower prices and shifts in pharmacy mix toward lower-reimbursement programs.
Regulatory/Legislative Changes → Revenues and Operating Results → Potential for reduced funding for government-sponsored programs (Medicare/Medicaid) and mandatory premium refunds under MLR requirements.
Cybersecurity Incidents → Operating Results and Financial Condition → Significant expenses for remediation, regulatory fines, and potential compensatory or punitive damages from litigation.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 8-K | Feb 2026 | — |
| 10-K | Feb 2026 | Dec 2025 |
| 10-Q | Oct 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
CVS Health Reaches Proposed FTC Settlement Regarding Insulin Pricing Practices
- ▸Proposed FTC settlement reached regarding insulin pricing
- ▸Leerink maintains Outperform rating with $98 price target
- ▸Analysts view settlement as positive reduction in PBM business uncertainty
- ▸Q1 earnings headwinds cited from lighter flu season and winter storms
- ▸Bernstein projects Aetna earnings to double over next three years
CVS Health proposes FTC settlement over Caremark insulin pricing as valuation concerns persist
- ▸Proposed FTC settlement regarding insulin pricing at Caremark pharmacy benefit unit
- ▸H1 2024 HCB segment revenue +23% YoY
- ▸Current P/E ratio 51.2x vs 21.2x healthcare industry average
- ▸1-year total shareholder return 9.33%
- ▸Market narrative estimates $104.01 fair value vs $71.18 current share price
CVS Health reaches proposed FTC settlement over Caremark insulin pricing practices
- ▸Proposed FTC settlement addresses insulin pricing at Caremark PBM unit
- ▸Quarterly dividend declared at $0.665 per share, payable May 4, 2026
- ▸Former Elevance Health CFO John E. Gallina elected to board
- ▸Projected 2029 revenue $445.5B with $10.2B in earnings
- ▸Regulatory scrutiny of PBM model remains primary risk to investment thesis
BrightSpring 2025 Revenue $12.9B +28% YoY; 2026 Outlook Focuses on Margin Expansion
- ▸FY2025 revenue $12.9B, up 28.2% from $10.1B in 2024
- ▸Pharmacy Solutions segment revenue $11.4B, representing 88.7% of total
- ▸Specialty and infusion Q4 revenue +43% YoY
- ▸Management expects 2026 profitability to grow faster than revenue
- ▸Platform serves 465,000 patients daily via 10,500 clinical providers and pharmacists
BrightSpring Q4 Revenue $3.55B +29% YoY, Adjusted EBITDA +41% to $184M
- ▸Q4 revenue $3.55B, up 29.3% YoY
- ▸Q4 adjusted EBITDA $184M, up 40.7% YoY
- ▸Q4 net income $49.6M, up from $4.3M YoY
- ▸FY26 revenue guidance $14.45B–$15.0B
- ▸FY26 adjusted EBITDA guidance $760M–$790M
CVS Health reaffirms 2026 GAAP EPS guidance of $5.94–$6.14 per share
- ▸Reaffirmed FY2026 GAAP diluted EPS guidance of $5.94–$6.14
- ▸Partnering with Google Cloud to launch AI-enabled consumer engagement platform in 2026
- ▸Bernstein upgraded stock to Outperform, raising price target to $94
- ▸Platform to utilize Google Gemini models, Cloud Healthcare API, and BigQuery
- ▸House Judiciary Committee issued subpoenas regarding potential ACA fraud investigation
CVS Health Q4 revenue $105.69B +8.2%, adjusted EPS $1.09 beats estimates
- ▸Q4 adjusted EPS $1.09, down 8.4% YoY, beating estimates by 10.1%
- ▸Q4 revenue $105.69B, up 8.2% YoY, exceeding estimates by 2.2%
- ▸FY2025 total revenue $402.07B, up 7.8% YoY
- ▸Health Services revenue $51.24B, up 9% YoY
- ▸Pharmacy & Consumer Wellness revenue $37.66B, up 12.4% YoY
Humana Q4 Revenue $32.64B +11.8% Beats Estimates, Full-Year EPS Guidance Misses
- ▸Humana Q4 revenue $32.64B, +11.8% YoY, beat estimates by 1.8%
- ▸Humana full-year EPS guidance missed analyst expectations significantly
- ▸Clover Health Q4 revenue $487.7M, +44.7% YoY, beat estimates by 4.4%
- ▸Molina Healthcare Q4 revenue $11.38B, +8.3% YoY, missed full-year EPS guidance
- ▸CVS Health Q4 revenue $105.7B, +8.2% YoY, beat estimates by 2%
CVS Health's Aetna pays $117.7 million to settle Medicare Advantage false claims allegations
- ▸$117.7 million settlement paid to resolve Medicare Advantage claims
- ▸Allegations involved submission of inaccurate diagnosis codes to inflate payments
- ▸Settlement resolves claims against Aetna subsidiary
- ▸DOJ alleged improper billing practices for Medicare Advantage plans
CVS Health's Aetna to pay $117.7 million to resolve False Claims Act allegations
- ▸$117.7 million settlement payment to resolve False Claims Act allegations
- ▸Alleged submission of false patient diagnosis data for Medicare Advantage plans
- ▸Inflated monthly payments obtained from Centers for Medicare and Medicaid Services
- ▸Settlement addresses improper billing practices within Aetna's Medicare Advantage segment